Log in
Enquire now
‌

HepaRegeniX

Small molecule MKK4 inhibitors developer to treat acute and chronic liver diseases.

OverviewStructured DataIssuesContributors

Contents

heparegenix.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Health technology
Health technology
Biomedical engineering
Biomedical engineering
Engineering
Engineering
Biotechnology
Biotechnology
Location
Germany
Germany
CEO
‌
Elias Papatheodorou
Pitchbook URL
pitchbook.com/profiles...168351-40
Number of Employees (Ranges)
1 – 10
Email Address
info@heparegenix.com
Phone Number
+4970717912810
Investors
Wellington Partners
Wellington Partners
High-Tech Gründerfonds
High-Tech Gründerfonds
‌
Novo A/S
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund
Founded Date
2017
Total Funding Amount (USD)
61,600,000
Latest Funding Round Date
April 15, 2025
Latest Funding Type
Series C
Series C
Patents Assigned (Count)
1
COO
‌
Wolfgang Albrecht
Country
Germany
Germany
Headquarters
Tübingen
Tübingen

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
24,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like HepaRegeniX

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.